AMANTADINE ER

Products Affected

Step 2:

- OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE
- OSMOLEX ER 193 MG TABLET, EXTENDED RELEASE
- OSMOLEX ER 258 MG TABLET, EXTENDED RELEASE

Details

Criteria	PRIOR CLAIM FOR AMANTADINE HCL IMMEDIATE RELEASE WITHIN THE PAST 120 DAYS.

ANTICONVULSANTS

Products Affected

Step 2:

- APTIOM 200 MG TABLET
- APTIOM 400 MG TABLET
- APTIOM 600 MG TABLET
- APTIOM 800 MG TABLET
- BANZEL 200 MG TABLET
- BANZEL 40 MG/ML ORAL SUSPENSION
- BANZEL 400 MG TABLET
- FYCOMPA 0.5 MG/ML ORAL SUSPENSION
- FYCOMPA 10 MG TABLET
- FYCOMPA 12 MG TABLET
- FYCOMPA 2 MG TABLET
- FYCOMPA 4 MG TABLET
- FYCOMPA 6 MG TABLET
- FYCOMPA 8 MG TABLET
- OXTELLAR XR 150 MG TABLET,EXTENDED RELEASE
- OXTELLAR XR 300 MG TABLET,EXTENDED RELEASE
- OXTELLAR XR 600 MG TABLET,EXTENDED RELEASE
- TROKENDI XR 200 MG CAPSULE, EXTENDED RELEASE

Details

Criteria	PRIOR CLAIM FOR GENERIC ANTICONVULSANT AGENT (CARBAMAZEPINE, DIVALPROEX SODIUM, GABAPENTIN, LAMOTRIGINE, LEVETIRACETAM, OXCARBAZEPINE, TIAGABINE, TOPIRAMATE, VALPROIC ACID, OR ZONISAMIDE), WITHIN THE PAST 120 DAYS.

ANTIDIABETIC AGENTS - MISCELLANEOUS

Products Affected

Step 2:

- GLYXAMBI 10 MG-5 MG TABLET
- GLYXAMBI 25 MG-5 MG TABLET
- INVOKAMET 150 MG-1,000 MG TABLET
- INVOKAMET 150 MG-500 MG TABLET
- INVOKAMET 50 MG-1,000 MG TABLET
- INVOKAMET 50 MG-500 MG TABLET
- INVOKAMET XR 150 MG-1,000 MG TABLET, EXTENDED RELEASE
- INVOKAMET XR 150 MG-500 MG TABLET, EXTENDED RELEASE
- INVOKAMET XR 50 MG-1,000 MG TABLET, EXTENDED RELEASE
- INVOKAMET XR 50 MG-500 MG TABLET, EXTENDED RELEASE
- INVOKANA 100 MG TABLET
- INVOKANA 300 MG TABLET
- JARDIANCE 10 MG TABLET
- JARDIANCE 25 MG TABLET
- SYNJARDY 12.5 MG-1,000 MG TABLET
- SYNJARDY 12.5 MG-500 MG TABLET
- SYNJARDY 5 MG-1,000 MG TABLET
- SYNJARDY 5 MG-500 MG TABLET
- SYNJARDY XR 10 MG-1,000 MG TABLET, EXTENDED RELEASE
- SYNJARDY XR 12.5 MG-1,000 MG TABLET, EXTENDED RELEASE
- SYNJARDY XR 25 MG-1,000 MG TABLET, EXTENDED RELEASE
- SYNJARDY XR 5 MG-1,000 MG TABLET, EXTENDED RELEASE

Details

Criteria	ST Criteria: Pending CMS Approval

ANTI-INFLAMMATORY AGENTS - GI

Products Affected

Step 2:

- DIPENTUM 250 MG CAPSULE

Details

Criteria	PRIOR CLAIM FOR ANY 1 OF THE FOLLOWING: BALSALAZIDE, APRISO, MESALAMINE DR 800 MG TAB, FORMULARY MESALAMINE 400 MG CAP(DRTAB) OR FORMULARY MESALAMINE 1.2 G DR TAB, WITHIN THE PAST 120 DAYS.

ANTIPSYCHOTIC AGENTS

Products Affected

Step 2:

- *aripiprazole 10 mg disintegrating tablet*
- *aripiprazole 15 mg disintegrating tablet*
- *clozapine 100 mg disintegrating tablet*
- *clozapine 12.5 mg disintegrating tablet*
- *clozapine 150 mg disintegrating tablet*
- *clozapine 200 mg disintegrating tablet*
- *clozapine 25 mg disintegrating tablet*
- FANAPT 1 MG TABLET
- FANAPT 10 MG TABLET
- FANAPT 12 MG TABLET
- FANAPT 1MG(2)-2 MG(2)-4MG(2)-6 MG(2) TABLETS IN A DOSE PACK
- FANAPT 2 MG TABLET
- FANAPT 4 MG TABLET
- FANAPT 6 MG TABLET
- FANAPT 8 MG TABLET
- SAPHRIS 10 MG SUBLINGUAL TABLET
- SAPHRIS 2.5 MG SUBLINGUAL TABLET
- SAPHRIS 5 MG SUBLINGUAL TABLET
- VERSACLOZ 50 MG/ML ORAL SUSPENSION
- VRAYLAR 1.5 MG (1)-3 MG (6) CAPSULES IN A DOSE PACK
- VRAYLAR 1.5 MG CAPSULE
- VRAYLAR 3 MG CAPSULE
- VRAYLAR 4.5 MG CAPSULE
- VRAYLAR 6 MG CAPSULE

Details

Criteria	PRIOR CLAIM FOR FORMULARY VERSIONS OF ANY TWO ORAL ANTIPSYCHOTICS: RISPERIDONE, CLOZAPINE TABLET, OLANZAPINE, IMMEDIATE RELEASE QUETIAPINE FUMARATE, ZIPRASIDONE, ARIPIPRAZOLE WITHIN THE PAST 365 DAYS.

ANTIPSYCHOTIC AGENTS II

Products Affected

Step 2:

- REXULTI 0.25 MG TABLET
- REXULTI 0.5 MG TABLET
- REXULTI 1 MG TABLET
- REXULTI 2 MG TABLET
- REXULTI 3 MG TABLET
- REXULTI 4 MG TABLET

Details

Criteria	PRIOR CLAIM FOR TWO (2) OF THE FOLLOWING FORMULARY ORAL VERSIONS OF ATYPICAL ANTIPSYCHOTICS (RISPERIDONE, CLOZAPINE, OLANZAPINE, QUETIAPINE, ARIPIPRAZOLE OR ZIPRASIDONE) OR SSRI (CITALOPRAM, ESCITALOPRAM, FLUOXETINE, PAROXETINE OR SERTRALINE) OR SNRI (DESVENLAFAXINE, DULOXETINE OR VENLAFAXINE) WITHIN THE PAST 365 DAYS

B VERSUS D ADMINISTRATIVE STEP

Products Affected

Step 2:

- CYCLOPHOSPHAMIDE 25 MG CAPSULE
- CYCLOPHOSPHAMIDE 50 MG CAPSULE
- *methotrexate sodium 2.5 mg tablet*
- XATMEP 2.5 MG/ML ORAL SOLUTION

Details

Criteria	IN ORDER TO ASSIST IN A PART B VS. D PAYMENT DETERMINATION, A PRIOR CLAIM SEEN FOR A RHEUMATOID ARTHRITIS, PSORIASIS OR ACTIVE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG WITHIN THE PAST 120 DAYS WILL QUALIFY FOR PART D PAYMENT. ALL OTHER INDICATIONS WILL HAVE A PART B VS. D PAYMENT DETERMINATION MADE THROUGH THE FORMULARY EXCEPTION PROCESS PRIOR TO THE APPROVAL OF THE DRUG.

ELUXADOLINE

Products Affected

Step 2:

- VIBERZI 100 MG TABLET
- VIBERZI 75 MG TABLET

Details

Criteria	PRIOR CLAIM FOR DICYCLOMINE AND XIFAXAN 550MG WITHIN THE PAST 365 DAYS.

FIDAXOMICIN

Products Affected

Step 2:

- DIFICID 200 MG TABLET

Details

Criteria	PRIOR CLAIM FOR ORAL VANCOMYCIN IN THE PAST 120 DAYS.

INSULIN/GLP-1 ANALOG

Products Affected

Step 2:

- SOLIQUA 100/33 100 UNIT-33 MCG/ML SUBCUTANEOUS INSULIN PEN
- XULTOPHY 100/3.6 100 UNIT-3.6 MG/ML (3 ML) SUBCUTANEOUS INSULIN PEN

Details

Criteria	ST Criteria: Pending CMS Approval

NASAL CORTICOSTEROIDS II

Products Affected

Step 2:

- XHANCE 93 MCG/ACTUATION BREATH ACTIVATED AEROSOL

Details

Criteria	PRIOR CLAIM FOR MOMETASONE NASAL SPRAY WITHIN THE PAST 120 DAYS.

NOVEL ORAL ANTICOAGULANTS

Products Affected

Step 2:

- PRADAXA 110 MG CAPSULE
- PRADAXA 150 MG CAPSULE
- PRADAXA 75 MG CAPSULE

Details

Criteria	PRIOR CLAIM FOR ELIQUIS AND XARELTO IN THE PAST 365 DAYS.

OPHTHALMIC ANTIHISTAMINES - NO OTC

Products Affected

Step 2:

- ALREX 0.2 % EYE DROPS,SUSPENSION

Details

Criteria	PRIOR CLAIM FOR FEDERAL LEGEND LEVOCETIRIZINE , CROMOLYN SODIUM, EPINASTINE, OR FORMULARY OLOPATADINE EYE DROPS WITHIN THE PAST 120 DAYS.

OPHTHALMIC PROSTAGLANDINS

Products Affected

Step 2:

- ROCKLATAN 0.02 %-0.005 % EYE DROPS

Details

Criteria	PRIOR CLAIM FOR FORMULARY VERSION OF LATANOPROST (GENERIC XALATAN OR XALATAN) AND ONE OF THE FOLLOWING: LUMIGAN 0.01%, TRAVATAN Z, ALPHAGAN P 0.1%, COMBIGAN, SIMBRINZA OR AZOPT WITHIN THE PAST 365 DAYS.

RENIN ANGIOTENSIN SYSTEM INHIBITORS

Products Affected

Step 2:

- TEKTURNA HCT 150 MG-12.5 MG TABLET
- TEKTURNA HCT 150 MG-25 MG TABLET
- TEKTURNA HCT 300 MG-12.5 MG TABLET
- TEKTURNA HCT 300 MG-25 MG TABLET

Details

Criteria	PRIOR CLAIM FOR AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR (ACE INHIBITOR), ACE INHIBITOR COMBINATION, GENERIC ANGIOTENSIN RECEPTOR BLOCKER (ARB), GENERIC ARB COMBINATION OR GENERIC DIRECT RENIN INHIBITORS WITHIN THE PAST 120 DAYS.

SPRITAM

Products Affected

Step 2:

- SPRITAM 1,000 MG TABLET FOR ORAL SUSPENSION
- SPRITAM 250 MG TABLET FOR ORAL SUSPENSION
- SPRITAM 500 MG TABLET FOR ORAL SUSPENSION
- SPRITAM 750 MG TABLET FOR ORAL SUSPENSION

Details

Criteria	PRIOR CLAIM FOR LEVETIRACETAM SOLUTION IN THE PAST 120 DAYS

INDEX

ALREX 0.2 % EYE DROPS,SUSPENSION 13
APTIOM 200 MG TABLET 2
APTIOM 400 MG TABLET 2
APTIOM 600 MG TABLET 2
APTIOM 800 MG TABLET 2
aripiprazole 10 mg disintegrating tablet 5
aripiprazole 15 mg disintegrating tablet 5
BANZEL 200 MG TABLET 2
BANZEL 40 MG/ML ORAL SUSPENSION 2
BANZEL 400 MG TABLET 2
clozapine 100 mg disintegrating tablet 5
clozapine 12.5 mg disintegrating tablet 5
clozapine 150 mg disintegrating tablet 5
clozapine 200 mg disintegrating tablet 5
clozapine 25 mg disintegrating tablet 5
CYCLOPHOSPHAMIDE 25 MG CAPSULE 7
CYCLOPHOSPHAMIDE 50 MG CAPSULE 7
DIFICID 200 MG TABLET 9
DIPENTUM 250 MG CAPSULE 4
FANAPT 1 MG TABLET 5
FANAPT 10 MG TABLET 5
FANAPT 12 MG TABLET 5
FANAPT 1MG(2)-2 MG(2)-4MG(2)-6 MG(2) TABLETS IN A DOSE PACK 5
FANAPT 2 MG TABLET 5
FANAPT 4 MG TABLET 5
FANAPT 6 MG TABLET 5
FANAPT 8 MG TABLET 5
FYCOMPA 0.5 MG/ML ORAL SUSPENSION 2
FYCOMPA 10 MG TABLET 2
FYCOMPA 12 MG TABLET 2
FYCOMPA 2 MG TABLET 2
FYCOMPA 4 MG TABLET 2
FYCOMPA 6 MG TABLET 2
FYCOMPA 8 MG TABLET 2
GLYXAMBI 10 MG-5 MG TABLET 3
GLYXAMBI 25 MG-5 MG TABLET 3
INVOKAMET 150 MG-1,000 MG TABLET 3
INVOKAMET 150 MG-500 MG TABLET 3
INVOKAMET 50 MG-1,000 MG TABLET 3
INVOKAMET 50 MG-500 MG TABLET 3
INVOKAMET XR 150 MG-1,000 MG TABLET, EXTENDED RELEASE 3
INVOKAMET XR 150 MG-500 MG TABLET, EXTENDED RELEASE 3
INVOKAMET XR 50 MG-1,000 MG TABLET, EXTENDED RELEASE 3
INVOKAMET XR 50 MG-500 MG TABLET, EXTENDED RELEASE 3
INVOKANA 100 MG TABLET 3
INVOKANA 300 MG TABLET 3
JARDIANCE 10 MG TABLET 3
JARDIANCE 25 MG TABLET 3
methotrexate sodium 2.5 mg tablet 7
OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE 1
OSMOLEX ER 193 MG TABLET, EXTENDED RELEASE 1
OSMOLEX ER 258 MG TABLET, EXTENDED RELEASE 1
OXTELLAR XR 150 MG TABLET,EXTENDED RELEASE 2
OXTELLAR XR 300 MG TABLET,EXTENDED RELEASE 2
OXTELLAR XR 600 MG TABLET,EXTENDED RELEASE 2
PRADAXA 110 MG CAPSULE 12
PRADAXA 150 MG CAPSULE 12
PRADAXA 75 MG CAPSULE 12
REXULTI 0.25 MG TABLET 6
REXULTI 0.5 MG TABLET 6
REXULTI 1 MG TABLET 6
REXULTI 2 MG TABLET 6
REXULTI 3 MG TABLET 6
REXULTI 4 MG TABLET 6
ROCKLATAN 0.02 %-0.005 % EYE DROPS 14
SAPHRIS 10 MG SUBLINGUAL TABLET 5

SAPHRIS 2.5 MG SUBLINGUAL TABLET 5
SAPHRIS 5 MG SUBLINGUAL TABLET 5
SOLIQUA 100/33 100 UNIT-33 MCG/ML SUBCUTANEOUS INSULIN PEN 10
SPRITAM 1,000 MG TABLET FOR ORAL SUSPENSION 16
SPRITAM 250 MG TABLET FOR ORAL SUSPENSION 16
SPRITAM 500 MG TABLET FOR ORAL SUSPENSION 16
SPRITAM 750 MG TABLET FOR ORAL SUSPENSION 16
SYNJARDY 12.5 MG-1,000 MG TABLET 3
SYNJARDY 12.5 MG-500 MG TABLET 3
SYNJARDY 5 MG-1,000 MG TABLET 3
SYNJARDY 5 MG-500 MG TABLET 3
SYNJARDY XR 10 MG-1,000 MG TABLET, EXTENDED RELEASE 3
SYNJARDY XR 12.5 MG-1,000 MG TABLET, EXTENDED RELEASE 3
SYNJARDY XR 25 MG-1,000 MG TABLET, EXTENDED RELEASE 3
SYNJARDY XR 5 MG-1,000 MG TABLET, EXTENDED RELEASE 3
TEKTURNA HCT 150 MG-12.5 MG TABLET 15
TEKTURNA HCT 150 MG-25 MG TABLET 15
TEKTURNA HCT 300 MG-12.5 MG TABLET 15
TEKTURNA HCT 300 MG-25 MG TABLET 15
TROKENDI XR 200 MG CAPSULE, EXTENDED RELEASE 2
VERSACLOZ 50 MG/ML ORAL SUSPENSION 5
VIBERZI 100 MG TABLET 8
VIBERZI 75 MG TABLET 8
VRAYLAR 1.5 MG (1)-3 MG (6) CAPSULES IN A DOSE PACK 5
VRAYLAR 1.5 MG CAPSULE 5
VRAYLAR 3 MG CAPSULE 5
VRAYLAR 4.5 MG CAPSULE 5
VRAYLAR 6 MG CAPSULE 5
XATMEP 2.5 MG/ML ORAL SOLUTION 7
XHANCE 93 MCG/ACTUATION BREATH ACTIVATED AEROSOL 11
XULTOPHY 100/3.6 100 UNIT-3.6 MG/ML (3 ML) SUBCUTANEOUS INSULIN PEN 10